Anti-Human HLA-A, B, C (MHC Class I) – Purified in vivo GOLD™ Functional Grade

Anti-Human HLA-A, B, C (MHC Class I) – Purified in vivo GOLD™ Functional Grade

Product No.: H263

[product_table name="All Top" skus="H263"]

- -
- -
Clone
W6/32
Target
HLA-A,B,C
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Major Histocompatibility Class I, MHC class I, human leukocyte antigen (HLA)
Isotype
IgG2a κ
Applications
B
,
FC
,
IHC FF
,
in vivo
,
IP
,
PhenoCycler®
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Baboon
Chimpanzee
Cynomolgus Monkey
Feline
Bovine
Human
Host Species
Mouse
Immunogen
Human tonsil cell membrane
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this HLA-A,B,C Clone W6/32 antibody for staining cells in flow cytometry is ≤ 2.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for for use in western blotting is 1-10 μg/ml.
Additional Applications Reported In Literature ?
B
CODEX®
IHC FF
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone W6/32 recognizes the human MHC class I molecules HLA-A, -B, and -C.
Background
HLA antibody, clone W6/32, recognizes the major histocompatibility complex (MHC) class I molecules human leukocyte antigen (HLA)-A, HLA-B, and HLA-C. MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)1,2. The α-chain consists of three domains (α1, α2, and α3)3. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens4-6. β2M noncovalently associates with α3, which is essential for MHC stability. MHC class I plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation7. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I, which helps augment TCR signaling8. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance9. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity10,11.
Antigen Distribution
HLA-A, -B, and -C are ubiquitously expressed on nucleated cells.

Antigen Details

Ligand/Receptor
CD3/TCR, CD8
Function
Antigen presentation
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

References & Citations

1. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25
2. Wieczorek M, et al. (2017) Front Immunol. 8:292
3. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9
4. Matsumura M, et al. (1992) Science. 257:927–34.10.1126/science.1323878
5. Bouvier M & Wiley DC. (1994) Science. 265:398–402.10.1126/science.8023162
6. Zacharias M & Springer S. (2004) Biophys J. 87:2203–14.10.1529/biophysj.104.044743
7. Cruz FM, et al (2017) Annu Rev Immunol. 35:149-176
8. Artyomov MN, et al (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
9. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856
10. Raulet DH. (1994) Adv Immunol. 55:381-421
11. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58
B
Flow Cytometry
IHC FF
in vivo Protocol
Immunoprecipitation Protocol
PhenoCycler®
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.